Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Teresa Molina-Garcia"'
Autor:
Manuel Cordoba-Diaz, Teresa Molina-Garcia, R Vázquez-Sánchez, Damián Cordoba-Diaz, J Sánchez-Rubio-Ferrández
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:1076-1081
Carboplatin hypersensitivity reactions are one of the major clinical challenges in treating patients with relapse/recurrent ovarian malignancies. Desensitization protocols allow the continuation of treatment in patients who have presented hypersensit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad1b993ab13f1e62980a0bdaa167dcd3
https://doi.org/10.1177/1078155218772885
https://doi.org/10.1177/1078155218772885
Autor:
José Miguel Martín Martínez, Teresa Molina-Garcia, Laura López-Esteban, Rocío Vázquez-Sánchez, Miguel Soria-Tristán, Laura Díaz-Paniagua, Ana Sanchez-Pena, Raúl Diez-Fernández, Santos Enrech-Frances
Publikováno v:
Journal of Oncology Pharmacy Practice. 24:511-516
Purpose Ethanol as an excipient is used to enhance the solubility of gemcitabine, but, sometimes, the dose of ethanol a patient may be given is much higher than the dose considered to be toxic. We aimed to assess ethanol-related symptoms and signs in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24d6d40815898ae2db26751fb9f00738
https://doi.org/10.1177/1078155217715790
https://doi.org/10.1177/1078155217715790
Autor:
Teresa Molina-Garcia, Á Aragón-Díez, JM Rodríguez-Heredia, I Cavada Carranza, J Sánchez-Rubio-Ferrandez, FJ Alonso-Zazo, ME Martínez-Núñez, R Vázquez-Sánchez
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Therapeutic decision-making for biologic-therapies (BT) dose optimisation should be based on optimal disease activity results. The goal of BT optimisation is to guarantee long-term effectiveness and safety, maximising economic savings. Pur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a7c27b24c729ccb99bfa284d921d907
https://doi.org/10.1136/ejhpharm-2019-eahpconf.290
https://doi.org/10.1136/ejhpharm-2019-eahpconf.290
Autor:
Rocío Vázquez Sánchez, Damián Cordoba-Diaz, Javier Sánchez-Rubio Ferrández, Teresa Molina-Garcia, Raúl Diez-Fernández, Manuel Cordoba-Diaz
Publikováno v:
Eur J Hosp Pharm
Desensitisation protocols allow the continuation of treatment in patients who have presented hypersensitivity reactions. Carboplatin desensitisation solutions are usually prepared in the chemotherapy centralised units of hospital pharmacies and they
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59bf2e558a0f9fb6af89b892c55960af
https://doi.org/10.1136/ejhpharm-2018-001746
https://doi.org/10.1136/ejhpharm-2018-001746
Autor:
Ana Sanchez-Pena, Teresa Molina-Garcia, Rocío Vázquez-Sánchez, Santos Enrech-Frances, Raúl Diez-Fernández
Publikováno v:
International journal of clinical pharmacy. 38(4)
Background The combination of cisplatin or carboplatin with vinorelbine is one of the standard regimens in non-small-cell lung cancer. Some studies have shown that the hemogram on day-8 could be avoided in patients with cisplatin. However, carboplati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::652186cd3136175b0d79981232b7ce34
https://pubmed.ncbi.nlm.nih.gov/27164956
https://pubmed.ncbi.nlm.nih.gov/27164956
Autor:
Teresa Molina-Garcia, Ana Sanchez-Pena, Raúl Diez-Fernández, Rocío Vázquez Sánchez, Santos Enrech-Frances
Publikováno v:
Journal of Clinical Oncology. 33:e17749-e17749
e17749 Background: The combination of platinum drugs (carboplatin, cisplatin), given on day 1, and vinorelbine, given on days 1 and 8, every 3 weeks is one of the standard regimens in several cance...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8f687f105c260fe7b5bb00940f18fce
https://doi.org/10.1200/jco.2015.33.15_suppl.e17749
https://doi.org/10.1200/jco.2015.33.15_suppl.e17749
Autor:
Teresa Molina-Garcia, J Sánchez-Rubio, P Rodríguez-Quesada, R Vázquez-Sánchez, J Ramón, L López-Esteban
Publikováno v:
European Journal of Hospital Pharmacy. 21:A51.2-A52
Background Tenofovir (TNF) is one of the most used antiretroviral drugs for treatment of HIV infection worldwide. Although well tolerated, effects of TNF on renal function are still of concern. Purpose To assess the incidence of tenofovir-associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acc5324c602e0c56c3a47fe2d8cda10f
https://doi.org/10.1136/ejhpharm-2013-000436.125
https://doi.org/10.1136/ejhpharm-2013-000436.125
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.